Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GP100 thanks for your research EOM
You wont be able... It was some hearsay that came from the Shareholders meeting... that is why I said "officially".
Listen, I or anybody else can say ANYTING we please, but that does not make the company saying it.
Can you please show just 1 place where the company officially used the "astronomical" word you are referring too? thx but there isnt any (at least I have not seen it)
This sort of things happen when you arive you are pushing the urologist to give youu something he has not played any part in it... so, in a nut shell he wrote 2mgs instead of 3 mgs...
He was not very pleased with my request (rather demand) so I guess he did not pay much attention to what he wrote... and wrote it wrong... Well, c'est la vie! Now I gotta to visit him again... and now he better writes everything WELL!
For those of you who were expecting some news from me... I am back from my trip to the UK. Unfortunately I had some issues with the prescription my urologist (back home) had made for me that did not meet the British standards and therefore the pharmacist could not accept it.
So I am back to square one, though I have made some arrangements to get some samples rather soon... I will keep you updated of this sort of soap opera
LOLLLL! Good one.... Putero a la fuerza!
Now seriously, what you mention about being the first shipment into the country makes me think that the package was also stored with customs for a while which means further delay and longer time out of the fridge... no way the product arrived in good conditions
During these last days temperatures have been VERY high in the area where Cartonet lives. Plus I do know that UPS (Spain) has no fridge service for all shipments while they are stocked... nor in the transportation vehicle.
It is very likely that the package was never treated as one needing cold chain... So 5 days on its own are too many for the "ice" protection Cartonet mentioned
Launch should have taken place in January??? Sure it would help
Guys, I am next on the list... I 'll be going to the UK next week and planning to try Vitaros... but to be honest with you I am not sure I feel like reporting back. A bit too many little jokes and stuff taking place here on the board...
FYI today is a holyday in many cities in Spain (like Barcelona) and many people took Monday off too ... So give him a break... and let him contribute to the board if he feels like contributing... I am sure he will otherwise he would not have announced it
Thx CP, A few years back Dr. Thorpe's gave a speech in Barcelona... I went there but unfortunately I had no chance of talking to him... The conference was too much of the "scholar" type... I mean too many ypung guys from Universities and Colleges and not that many from the Biotech Companies... I wonder if ASCO is something similar
Hey CP, you mention some conferences in Madrid. I guess I missed that post (too many to follow right now). Do you have any info in regard conferences in Spain...? I wouldnt mind attending them. thx
Not yet though. Vitaros needs to be aproved there first
Well Apri would benefit the most if urologists all over the world are educated regarding Vitaros.... Regardless who should responsible for the efication
Takeda's? What about Apri? Takeda only is concerns about the UK. Apri the whole world
My urologist had the same opinion. He thought Vitaros to be another replica of Muse. I guess that is a problem that should be addressed by Apri
No problem Dave!.The only thing is that it may take a while until I am back homa and I use it.
Yeah I got it! Though nowadays with the Internet there may not be needed
Regarding my conversation with the doctor I need to do some research
regarding Muse vs. Vitaros. I know is a "supository". What I dont know is how efective it is bringing Alprostradil into the organism
Any "doctors" around with any knowledge?
I dont know either how hard it is inserting the supository in the pennis.... uggg it hurts just to think of it
I am planning to travel to the UK next week. So yesterday I went to an urologist to get a prescription for Vitaros. I just want to have a first hand knowledge of my investment. The urologisy said to know about Vitaros (or so he seemed) though he kept comparing it to Muse and thought they were about the same... (thought that Viagra, Cialis, etc were more effective) I tried to convince him otherwise... but of course he was "the expert". My conclusion from that visit is that Urologists may be a bunch of proud "know it all"s and that people using it might be the best way for Vitaros to become a success (if the product works as Apri claims)
<<Other cancer vaccines are also forecast to hit the glioblastoma market by 2019, including Celldex Therapeutics' Rindopepimut and Peregrine Pharmaceuticals' targeted therapy Cotara. But with few other prospects that offer significant overall survival rates, a large need for glioblastoma therapies will likely still remain.>>
My apologies if already posted
http://www.fiercevaccines.com/story/northwest-bio-leads-german-cancer-vax-trial-glioblastoma-market-poised-doub/2014-06-12
Northwest Bio begins German vax trial as glioblastoma market poised to double
June 12, 2014 | By Emily Mullin
SHARE
Northwest Biotherapeutics ($NWBO) has begun enrolling patients in a Phase III trial of its controversial dendritic cell-based therapeutic vaccine DCVax-L in Germany.
DCVax-L is meant to be used as an add-on to the standard treatment in newly diagnosed patients. The company has trumpeted the drug's potential and some analysts have been willing to oblige, saying that a successful launch of DCVax-L could propel overall sales in the glioblastoma multiforme drug market from $305 million in 2012 to $583 million in 2019, according to market research.
While the company has heralded individual success stories of patients in a Phase I/II study of DCVax-L living well beyond the expected survival time, critics have said that the data seen so far from a small cadre of patients shouldn't be considered statistically significant because of the trial's size and "informal nature." And TheStreet's Adam Feuerstein has railed against the company, harshly assailing the therapy as little more than a placebo--a position the company has repeatedly rejected.
The Biotech Primer: An insider's guide to the science driving the biotech and pharma industries
This 200-page book takes an in-depth look at the biotech industry and the science that drives it. Although the industry itself is constantly changing, these fundamental concepts upon which it is built will remain important for years to come - and decision-makers who understand these fundamentals will be better able to evaluate and predict new trends. Click here to buy today!
Sign up for our FREE newsletter for more news like this sent to your inbox!
In March, German health officials granted Bethesda, MD-based Northwest special permission to sell DCVax-L for all glioma brain cancers. Now, the company says its first trial site has opened in Dresden with three more trial sites expected to open this month and another four to open in July.
The news in March that a Phase III trial of Northwest's DCVax-L was on track pleased investors, sending its shares up by as much as 10%. In the midtrial review, Northwest's data monitoring board reviewed safety data and recommended the trial continue despite the omission of still-pending efficacy data.
The most lethal form of brain cancer, glioblastoma multiforme has a maximum overall survival of 15 months with the standard treatment of care--resection surgery, radiation therapy and chemotherapy with Merck's ($MRK) Temodar. For recurrent tumors, patients have the option of Roche's ($RHHBY) Avastin, carmustine and other chemotherapy drugs used off-label. But these only offer limited benefit in extending overall survival, leaving huge unmet need for better treatments.
Other cancer vaccines are also forecast to hit the glioblastoma market by 2019, including Celldex Therapeutics' Rindopepimut and Peregrine Pharmaceuticals' targeted therapy Cotara. But with few other prospects that offer significant overall survival rates, a large need for glioblastoma therapies will likely still remain.
- read the statement from Northwest Biotherapeutics
- get the market report press release
thx for the info... I will be listening... and watching too?
Renewable Energy Group completes Dynamic Fuels acquisition
http://www.yourrenewablenews.com/renewable+energy+group+completes+dynamic+fuels+acquisition_102059.html
Renewable Energy Group, Inc. (NASDAQ: REGI) announced today that its wholly-owned subsidiary, REG Synthetic Fuels, LLC, has completed its acquisition of the remaining 50% ownership interest in Dynamic Fuels, LLC, previously owned by Tyson Foods, Inc. (NYSE: TSN).
“Closing these transactions enables our entry into the renewable diesel market in a significant way”
As a result of last Tuesday’s closing of its purchase of substantially all of the assets of Syntroleum Corporation and the closing of this transaction with Tyson, REG now takes full ownership of Dynamic Fuels’ 75-million gallon nameplate capacity renewable diesel biorefinery in Geismar, Louisiana.
Tyson and Syntroleum formed Dynamic Fuels in 2007 as a 50/50 joint venture. Completed in 2010, the facility is the first large-scale renewable diesel biorefinery built in the U.S. and will now be known as REG Geismar, LLC.
“Closing these transactions enables our entry into the renewable diesel market in a significant way,” said Daniel J. Oh, Renewable Energy Group, Inc. President and Chief Executive Officer. “We are excited about the opportunity to offer new products to our customers, while building on our core competencies in research, engineering, production, and distribution of advanced biofuels. We look forward to bringing the Geismar biorefinery online and work to do so has begun.”
REG paid Tyson approximately $16.5 million in cash at closing and retired approximately $13.5 million of Dynamic Fuels’ indebtedness to Tyson. REG has also agreed to make up to $35 million in future payments to Tyson tied to product volumes at the Geismar biorefinery over a period of up to eleven and a half years. REG intends to use proceeds from its recent $143,750,000 convertible senior notes offering to either replace the letter of credit that Tyson Foods obtained to support the biorefinery’s $100 million in Gulf Opportunity Zone Bonds, issued through the Louisiana Public Facilities Authority, or to redeem these bonds.
Good reasoning Jeff, I agree EOM
You bet... I would (and will LOL)
what if they decide to buy a few
million shares
PPHM on the news (sorry if already posted)...
http://www.marketnewscall.com/volume-alert-clovis-oncology-inc-nasdaqclvs-inovio-pharmaceuticals-inc-nysemktino-peregrine-pharmaceuticals-nasdaqpphm/1226736/
Peregrine Pharmaceuticals (NASDAQ:PPHM)’s shares climbed 2.63% to $1.76. The company on Apr. 23 announced the opening of an investigator-sponsored trial (IST) of its investigational immunotherapy bavituximab in combination with Bristol-Myers Squibb’s ipilimumab (Yervoy®), for the treatment of advanced melanoma. Bavituximab is an upstream immune checkpoint inhibitor that targets phosphatidylserine (PS), a highly immunosuppressive molecule exposed on cells that line tumor blood vessels and tumor cells. Preclinical data in a model of melanoma demonstrate that the combination of a bavituximab equivalent and ipilimumab yield enhanced anti-tumor activity compared to ipilimumab alone.
I just talked to my brother who works (as a doctor) in one of the Hospitals enrolling patients (Spain). In case he gets any not classified info he will tell me (number of patients, doctors' opinion, etc)
Just another little grain of sand
Thx Bio... I am sure it will be an interesting webcast ...
https://events-na8.adobeconnect.com/content/connect/c1/1136537785/en/events/event/shared/default_template/event_registration.html?sco-id=1302427299
Definitely. They just gave little info... from which you could not get any meaningful conclusion
So your point is... ? You just doubt PPHM will get a partner? Ever?
I guess you imply that Bavi does not work... Can you please give us some reasons for that... besides guessing that thousands of bio scientists dont believe in it?
thank you
Right CP, I remember SK stating he was particularly interested in the Liver Cancer Trial
It is a good thing people talk about PPHM
http://www.techsonian.com/stocks-to-keep-your-eyes-on-peregrine-pharmaceuticals-pphm-american-rlty-cap-healthcare-tr-inc-hct-dyax-corp-dyax-neuralstem-inc-cur/12190008/
Stocks to Keep Your Eyes on – Peregrine Pharmaceuticals (PPHM), AMERICAN RLTY CAP HEALTHCARE TR INC (HCT), Dyax Corp (DYAX), Neuralstem, Inc (CUR)
SUBMITTED BY ALLSTAR STOCKPICKS ON MAY 15, 2014 - 01:43 PM
Birmingham, West Midlands — (TechSonian) — 15 May 2014 —Peregrine Pharmaceuticals (NASDAQ:PPHM) recently declared the opening of an investigator-sponsored trial (IST) of its investigational immunotherapy bavituximab in combination with Bristol-Myers Squibb’s ipilimumab (Yervoy®), for the treatment of advanced melanoma.
Peregrine Pharmaceuticals (NASDAQ:PPHM) gained 1.73%, trading on 1.06 million shares, to end the trade at $1.76. The stock changed hands in a range of $1.71 to $1.80, bringing its market capitalization to about $310.61 million.
GreaT News! Rambus Rejoins JEDEC... I find this to be very bullish.
Good job Ron Black!
http://www.eetimes.com/document.asp?doc_id=1322370&piddl_msgid=299463#msg_299463
What i think it is interesting is that when out of the cold chain(refrigerator) it has a life of 3 days
I also wonder if the temperature issue comes only once the "recipient" has been open. Maybe the product is "wrapped" in such a way that temperature is a non-issue. That would make sense considering long transportation periods.
THX for your reply... I wondered if in the EU you could buy a drug with the prescription signed by a doctor from another EU country... I googled and found this:
<<A prescription delivered by a doctor in your country is valid in all EU countries. However, medicine prescribed in one country might not be available in another, or it may bear another name.>>
http://europa.eu/youreurope/citizens/health/help-from-the-pharmacy/prescription/index_en.htm
I also emailed Recordati in Spain to gater info about Vitaros launch... I will post the reply if any.
ps. Todavía tenemos un café pendiente en Barcelona
Good find D., there is however something that does not click for me... Takeda clearly stated that Vitaros would only be sold at UK pharmacies ??? Anyway I hope you are right...
Thx Carlo for the info... interesting the note: you can only get from UK pharmacies
The question is: Does COTARA work or not? If it does the word "success" is appropriate. They might have administered their resources better but... I repeat taking a drug (that is effective) to a phaseIII is a successful event... However if my intention were to discredit the BOD... Since nobody is perfect I am sure you will be able to find one million reasons to do so. But I for one would not have my money in company whose BOD I believe is a disaster... I would leave to greener pastures
The fact that COTARA is in phase III is an accomplishment IMO. It means the drug is good enough to be there.
You cannot expect a small company to spend a money they dont have doing in all sorts of trials. You have to choose just the most efficient ones and stick to them. COTARA can wait, patients I am afraid they cant but that is another story where politicians should do something about
More about Recordati... Hope this has not been posted
http://www.thepharmaletter.com/article/recordati-posts-sales-growth-and-significant-margin-improvement-in-1st-qtr-2014
Business development news
In February, an exclusive license agreement was entered into with USA-based Apricus Biosciences for the marketing and sales of Vitaros (alprostadil), an innovative topical product for the treatment of erectile dysfunction, in certain Western European countries including, among others, Spain, European Union member countries in Central and Eastern Europe, Russia, Ukraine and the Commonwealth of Independent States (CIS), Turkey and certain African countries. Vitaros is approved for the treatment of erectile dysfunction by a number of European health authorities and by Health Canada.
“The first quarter results are particularly positive; the consolidation of the new companies acquired at the end of 2013 and the performance of our product portfolio have allowed us to further improve our profitability,” commented Giovanni Recordati, chairman and chief executive, adding: “For the full year 2014 we confirm our expectations to achieve operating income of more than 220 million euros and net income of more than 150 million euros thanks to margin improvement. Revenues, as of today, are expected to be slightly below 1,000 million euros due to a significant negative currency effect.”
LOL CP, great post. I loved it